• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD40 在癌症治疗中的生物学和临床应用。

Biology and clinical applications of CD40 in cancer treatment.

机构信息

Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

出版信息

Semin Oncol. 2010 Oct;37(5):517-23. doi: 10.1053/j.seminoncol.2010.09.002.

DOI:10.1053/j.seminoncol.2010.09.002
PMID:21074067
Abstract

CD40 is a costimulatory molecule widely expressed by immune cells and by neoplastic cells of different histotypes. Engagement of surface CD40 mediates different effects depending on cell type and microenvironment. In particular, CD40 expression on immune cells regulates humoral and cellular immunity, while it has apoptotic and antiproliferative activity on selected neoplastic cells. Thus, CD40 targeting may indirectly affect tumor growth through the activation of immune cells and/or directly by mediating cytotoxic effects on neoplastic cells. Preliminary findings emerging from clinical trials indicate that antibodies to CD40 can induce immune modulation and clinical responses in cancer patients.

摘要

CD40 是一种共刺激分子,广泛表达于免疫细胞和不同组织类型的肿瘤细胞表面。表面 CD40 的结合根据细胞类型和微环境的不同而介导不同的效应。特别是,免疫细胞表面的 CD40 表达调节体液和细胞免疫,而在某些肿瘤细胞上则具有凋亡和抗增殖活性。因此,CD40 靶向治疗可通过激活免疫细胞间接影响肿瘤生长,或通过对肿瘤细胞发挥细胞毒性作用而直接影响肿瘤生长。临床试验中的初步研究结果表明,抗 CD40 抗体可诱导癌症患者的免疫调节和临床应答。

相似文献

1
Biology and clinical applications of CD40 in cancer treatment.CD40 在癌症治疗中的生物学和临床应用。
Semin Oncol. 2010 Oct;37(5):517-23. doi: 10.1053/j.seminoncol.2010.09.002.
2
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.使用新型CD40激动剂单克隆抗体CP-870,893治疗的癌症患者的临床活性和免疫调节
J Clin Oncol. 2007 Mar 1;25(7):876-83. doi: 10.1200/JCO.2006.08.3311.
3
Prospect of targeting the CD40 pathway for cancer therapy.以CD40通路为靶点进行癌症治疗的前景。
Clin Cancer Res. 2007 Feb 15;13(4):1083-8. doi: 10.1158/1078-0432.CCR-06-1893.
4
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.达西珠单抗,一种用于治疗血液系统恶性肿瘤的抗CD40人源化单克隆抗体。
Curr Opin Investig Drugs. 2009 Jun;10(6):579-87.
5
Prospects for CD40-directed experimental therapy of human cancer.针对人类癌症的CD40定向实验性治疗的前景。
Cancer Gene Ther. 2003 Jan;10(1):1-13. doi: 10.1038/sj.cgt.7700527.
6
Clinical development of the anti-CTLA-4 antibody tremelimumab.抗 CTLA-4 抗体 tremelimumab 的临床开发。
Semin Oncol. 2010 Oct;37(5):450-4. doi: 10.1053/j.seminoncol.2010.09.010.
7
Beyond ipilimumab: new approaches target the immunological synapse.除了伊匹单抗之外:新方法瞄准免疫突触。
J Natl Cancer Inst. 2011 Jul 20;103(14):1079-82. doi: 10.1093/jnci/djr281. Epub 2011 Jul 7.
8
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.利妥昔单抗作为自体干细胞移植辅助治疗后,非霍奇金淋巴瘤患者CD27、CD40和CD80阳性B细胞的延迟再分布及体外免疫球蛋白产生受损。
Br J Haematol. 2007 May;137(4):349-54. doi: 10.1111/j.1365-2141.2007.06584.x.
9
CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells.激动型抗 CD40 单克隆抗体 5C11 通过 CD40 信号转导对胃癌细胞生物学行为的影响。
Immunol Lett. 2010 Jul 8;131(2):120-5. doi: 10.1016/j.imlet.2010.02.007. Epub 2010 Feb 25.
10
An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.一种针对CD40的激动剂抗体在体外自体肿瘤细胞/淋巴结细胞混合模型中可诱导树突状细胞成熟并促进自体抗肿瘤T细胞反应。
Scand J Immunol. 2007 May;65(5):479-86. doi: 10.1111/j.1365-3083.2007.01927.x.

引用本文的文献

1
The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment.CD40激动剂抗体疗法对胰腺癌微环境的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep 10. doi: 10.1007/s00210-025-04532-x.
2
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies.黑色素瘤、胃肠道及肺部恶性肿瘤的免疫疗法
AIMS Public Health. 2015 Mar 24;2(1):86-114. doi: 10.3934/publichealth.2015.1.86. eCollection 2015.
3
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.快速激活肿瘤相关巨噬细胞可增强预先存在的肿瘤免疫。
J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.
4
The use of immunotherapy in the treatment of melanoma.免疫疗法在黑色素瘤治疗中的应用。
J Hematol Oncol. 2017 Apr 24;10(1):88. doi: 10.1186/s13045-017-0458-3.
5
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy.利用免疫监视:癌症免疫治疗的当前进展与未来方向
Immunotargets Ther. 2014 Dec 4;3:151-65. doi: 10.2147/ITT.S37790. eCollection 2014.
6
CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.CD40配体在低度浆液性卵巢肿瘤细胞中诱导依赖RIP1的、坏死性凋亡样细胞死亡,但在浆液性交界性卵巢肿瘤细胞中则不然。
Cell Death Dis. 2015 Aug 27;6(8):e1864. doi: 10.1038/cddis.2015.229.
7
Immune checkpoint blockade and interferon-α in melanoma.黑色素瘤中的免疫检查点阻断与干扰素-α
Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14.
8
Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.肿瘤内注射Ad-ISF35(嵌合型CD154)可打破免疫耐受并诱导淋巴瘤肿瘤消退。
Hum Gene Ther. 2015 Jan;26(1):14-25. doi: 10.1089/hum.2014.015.
9
Functional significance of mononuclear phagocyte populations generated through adult hematopoiesis.成年造血过程中产生的单核吞噬细胞群体的功能意义。
J Leukoc Biol. 2014 Dec;96(6):969-80. doi: 10.1189/jlb.1RI0414-195R. Epub 2014 Sep 15.
10
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".癌症治疗中的免疫检查点阻断:双刃剑交叉靶向宿主作为“无辜的旁观者”。
Toxins (Basel). 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914.